Synthesis and Evaluation of Cytotoxic Activity of Substituted  N-(9-oxo-9H-xanthen-4-yl)benzenesulfonamides by Motavallizadeh, Somayeh et al.
University of Rhode Island
DigitalCommons@URI
Biomedical and Pharmaceutical Sciences Faculty
Publications Biomedical and Pharmaceutical Sciences
2013
Synthesis and Evaluation of Cytotoxic Activity of
SubstitutedN-(9-oxo-9H-
xanthen-4-yl)benzenesulfonamides
Somayeh Motavallizadeh
Asal Asal Fallah-Taftia
See next page for additional authors
Follow this and additional works at: https://digitalcommons.uri.edu/bps_facpubs
The University of Rhode Island Faculty have made this article openly available.
Please let us know how Open Access to this research benefits you.
This is a pre-publication author manuscript of the final, published article.
Terms of Use
This article is made available under the terms and conditions applicable towards Open Access Policy
Articles, as set forth in our Terms of Use.
This Article is brought to you for free and open access by the Biomedical and Pharmaceutical Sciences at DigitalCommons@URI. It has been accepted
for inclusion in Biomedical and Pharmaceutical Sciences Faculty Publications by an authorized administrator of DigitalCommons@URI. For more
information, please contact digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Motavallizadeh, S., Fallah-Tafti, A., Maleki, S., Shirazi, A. N., Pordeli, M., Safavi, M.,...Akbarzadeh, T. (2014). Synthesis and evaluation
of cytotoxic activity of substituted N-(9-oxo-9H-xanthen-4-yl)benzenesulfonamides. Tetrahedron Letters, 55(2), 373-375. doi:
10.1016/j.tetlet.2013.11.033
Available at: http://dx.doi.org/10.1016/j.tetlet.2013.11.033
Authors
Somayeh Motavallizadeh, Asal Asal Fallah-Taftia, Saeedeh Maleki, Amir Nasrolahi Shirazi, Mahboobeh
Pordeli, Maliheh Safavi, Sussan Kabudanian Ardestani, Shaaban Asd, Rakesh Tiwari, Donghoon Oh, Abbas
Shafiee, Alireza Foroumadi, Keykavous Parang, and Tahmineh Akbarzadeh
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/bps_facpubs/18
Graphical Abstract 
 
 
Synthesis and evaluation of cytotoxic activity of substituted 
 N-(9-oxo-9H-xanthen-4-yl)benzenesulfonamides 
Somayeh Motavallizadeha, Asal Fallah-Taftia, Saeedeh Malekia, Amir Nasrolahi Shirazic, Mahboobeh Pordelib, 
Maliheh Safavib, Sussan Kabudanian Ardestanib, Shaaban Asdc, Rakesh Tiwaric,d, Donghoon Ohc, Abbas 
Shafieea, Alireza Foroumadia, Keykavous Parangc,d,*, Tahmineh Akbarzadeha,*  
 
 
 
Leave this area blank for abstract info. 
 1 
 
 
 
Synthesis and evaluation of antiproliferative activity of substituted N-(9-oxo-9H-
xanthen-4-yl)benzenesulfonamides 
Somayeh Motavallizadeha, Asal Fallah-Taftia, Saeedeh Malekia, Amir Nasrolahi Shirazic, Mahboobeh 
Pordelib, Maliheh Safavib, Sussan Kabudanian Ardestanib, Shaaban Asdc, Rakesh Tiwaric,d, Donghoon Ohc, 
Abbas Shafieea, Alireza Foroumadia, Keykavous Parangc,d,*, Tahmineh Akbarzadeha,*  
aDepartment of Medicinal Chemistry, Faculty of Pharmacy and Drug Design & Development Research Center, Tehran University of Medical Sciences, Tehran, 
Iran 
bInstitute of Biochemistry and Biophysics, Department of Biochemistry, University of Tehran, Tehran, Iran 
cDepartment of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, 02881, USA 
dSchool of Pharmacy, Chapman University, Orange, CA, 92866, USA 
Cancer is known as one of the leading causes of mortality 
throughout the world, a disease characterized by uncontrolled cell 
growth, metastasis, and invasion. Inhibition of cancer cell 
proliferation is one of the most important principles in the 
treatment of cancer using anticancer compounds. The difficulty 
to diagnose the disease at the earlier stages, narrow therapeutic 
indices of chemotherapeutic agents, and the development of 
multidrug resistance are some of the major obstacles, which has 
made cancer treatment challenging and caused high mortality rate 
worldwide.1,2 
Among different classes of chemotherapeutic agents, 
compounds that act by DNA intercalation, such as the 9-
anilinoacridine amsacrine and the xanthone derivative 
dimethylxanthenone-4-acetic acid (DMXAA) have attracted 
particular attention, due to their high therapeutic potential. The 
data for xanthone binding studies with DNA indicate that the 
planar tricycle moiety serves as an important feature for 
designing new DNA intercalators.3-6 
In addition, sulfonamide derivatives have been found to 
possess potent anticancer activities through a variety of 
mechanisms such as cell cycle perturbation in the G1 phase, 
disruption of microtubule assembly, angiogenesis inhibition, and 
functional suppression of the transcriptional activator NF-Y.7-9 
Based on the diverse biological activities of the xanthones and 
aryl sulfonamides, we designed and synthesized a series of novel 
hybrid compounds containing both xanthone and sulfonamide 
entities in one molecule and evaluated them for their 
antiproliferative activity.  
The general procedure for the synthesis of substituted N-(9-
oxo-9H-xanthen-4-yl) benzenesulfonamide 5a-i and 6a-g is 
depicted in Scheme 1. 2-(2-Nitrophenoxy)benzoic acid (1) was 
prepared according to the previously reported method.10,11 
Compound 1 underwent cyclization in the presence of sulfuric 
acid (H2SO4) under reflux conditions to afford nitro-9H-xanthen-
9-one 2.12 Subsequent reaction of 2 with stannous chloride 
dehydrates in concentrated hydrochloric acid afforded 
corresponding amino-9H-xanthen-9-one 3. Finally, the reaction 
of 3 with the substituted benzenesulfonamide 4 in the presence of 
triethylamine in chloroform afforded N-(9-oxo-9H-xanthen-4-
yl)benzenesulfonamides 5a-i and 6a-g. The chemical structures 
of final products were confirmed with 1H NMR, 13C NMR, and 
mass spectroscopy.  
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Several novel N-(9-oxo-9H-xanthen-4-yl)benzenesulfonamides derivatives were prepared as 
potential antiproliferative agents. The in vitro antiproliferative activity of the synthesized 
compounds was investigated against a panel of tumor cell lines including breast cancer cell lines 
(MDA-MB-231, T-47D) and neuroblastoma cell line (SK-N-MC) using MTT colorimetric 
assay. Etoposide, a well-known anticancer drug, was used as a positive standard drug. Among 
synthesized compounds, 4-methoxy-N-(9-oxo-9H-xanthen-4-yl)benzenesulfonamide (5i)
showed the highest antiproliferative activity against MDA-MB-231, T-47D, and SK-N-MC 
cells. Furthermore, pentafluoro derivatives 5a and 6a exhibited higher antiproliferative activity 
than doxorubicin against human leukemia cell line (CCRF-CEM) and breast adenocarcinoma 
(MDA-MB-468) cells. Structure-activity relationship studies revealed that xanthone 
benzenesulfonamide hybrid compounds can be used for development of new lead anticancer 
agents. 
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Scheme 1. Reagents and conditions:  (a) H2SO4, reflux, 30 min; (b) SnCl2, conc. HCl, 100 °C, 4 h then NaOH 10%, RT, 30 min; 
(c) Et3N, CHCl3, RT. 
 
  
Table 1-Antiproliferative activity (IC50, in µM) of compounds against different cancer cell lines, neuroblastoma cell line (SK-N-
MC) and breast cancer cell line (MDA-MB-231, T-47D). 
Compounds X Y SK-N-MC 
IC50 (µM) 
MDA-MB-231 
IC50 (µM) 
T-47D 
IC50 (µM) 
5a H Penta F 58.7±30.8 85±15.9 53.9±4.7 
5b H 3-Cl >100 >100 58.6±1.8 
5c H 4-Cl >100 83.3±26.9 33.8±9.3 
5d H 2,5-di-Cl 95.8±28 >100 53.3±4.5 
5e H 2,4,5-tri Cl 78.5±6.4 60.4±17.2 36.3±9.2 
5f H 3-Cl,2-CH3 38.3±4.7 67.5±8.3 56.5±28.7 
5g H 4-Br 47.9±20.7 85.4±24.7 63.4±9.8 
5h H 4-NO2 90.9±16.4 96.3±49.2 52.7±22.4 
5i H 4-OCH3 25.2±26.5 54.4±21 19.7±0.18 
6a Cl Penta F 40.8±8.2 40.2±4.6 39±18 
6b Cl 3-Cl 40.5±28.3 59.5±37 83.±513 
6c Cl 2,4,5-tri-Cl 24.9±16.1 66.7±9.7 67.9±6.7 
6d Cl 3-Cl,2-CH3 41.3±23.5 30.4±5.9 49.3±26.7 
6e Cl 4-Br 37.1±12.7 45.3±3.8 46.9±17 
6f Cl 4-NO2 >100 63.1±20.7 76.1±1.6 
6g Cl 4-OCH3 >100 62.3±0.2 45±11.3 
Etoposide - - 33.4±11.7 36.6±5.9 32.7±5.5 
 
The antiproliferative activities of compounds 5a-i and 6a-g 
were evaluated by MTT reduction assay against two different 
breast cancer cell lines (MDA-MB-231 and T-47D) and a 
neuroblastoma cell line (SK-N-MC) (Table 1). Compound 5i 
containing a 4-methoxy group on the phenyl ring was the most 
potent compound in this series against these three cell lines. This 
compound exhibited higher antiproliferative activity against SK-
N-MC (IC50 = 25.2 µM) and T-47D (IC50 = 19.7 µM) cell lines 
when compared with etoposide. Compound 5i showed 1.7-fold 
higher antiproliferative activity against T-47D cell line when 
compared with control drug etoposide (IC50 = 32.7 µM). 
In general, the compounds were more potent against SK-N-
MC cell line when compared with other tested cell lines. 
Compounds 5i and 6c exhibited higher antiproliferative activity 
(IC50 = 24.9-25.2 µM) against SK-N-MC cell line in comparison 
with etoposide (IC50 = 33.4 µM). 3-Chloro-2-methylbenzene 
sulfonamide analog 6d with IC50 value of 30.4 µM showed 
higher antiproliferative activity than etoposide against MDA-
MB-231 cell line.  
Structure-activity relationship studies revealed that the 
antiproliferative activity of synthesized compounds was partly 
influenced by the type of substituents positioned on the phenyl 
ring. Most of the compounds bearing chlorine substitution in the 
6 position of xanthone ring showed generally more 
antiproliferative activity compared with the corresponding 
compounds without the chlorine moiety (6a, 6b, 6c, 6e versus 5a, 
5b, 5c, 5d, 5e, 5g, respectively).  
Among the compounds without a substituted chlorine on the 
xanthone ring, compound 5i with a 4-methoxy group on 
benzenesulfonamide ring was the most potent compound,  
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Figure 1. Inhibition of HCT-116, CCRF-CEM, and MDA-MB-468 cells by compounds 5a-i and 6a-g (50 µM) after 24 h 
incubation. The results are shown as the percentage of the control DMSO that has no compound (set at 100%). All the 
experiments were performed in triplicate (± SD). 
 
suggesting that the presence of an electron donor group on 
benzenesulfonamide ring increases the antiproliferative activity 
in this series of compounds. Introducing a methyl group in the 
position 2 of the benzenesulfonamide ring in compound 5f led to 
significant increased antiproliferative activity compared to 
compound 5b. Similarly, compound 6d with 2-methyl 
substitution showed enhanced antiproliferative activity compared 
to 6b suggesting that methyl substitution in position 2 of the 
benzenesulfonamide ring could result to increased 
antiproliferative activity in both substituted xanthone series of 
compounds with or without chlorine group. 
Alternatively, antiproliferative activity of substituted 
benzenesulfonamides derivatives were evaluated against human 
leukemia (CCRF-CEM), breast adenocarcinoma (MDA-MB-
468), and colorectal carcinoma (HCT-116) cell lines at the 
concentration of 50 µM (Figure 1) to determine whether the 
compounds are consistently cytotoxic against other cancer cell 
lines and to compare their activity with doxorubicin (Dox). 
Compounds 5a, 5c, 6a, and 6d exhibited consistent 
antiproliferative activity against all three cell lines. Among all the 
compounds, compounds 5a and 6a exhibited the highest 
antiproliferative activity against all the cell lines. For example, 
compound 6a inhibited the cell proliferation of HCT-116 (86%), 
CCRF-CEM (75%), and MDA-MB-468 (65%). Structure-activity 
relationship (SAR) revealed that the presence of five fluorine on 
the second ring improved the antiproliferative activity 
significantly (5a and 6a) against these three cell lines. 
Compounds 5a (79 and 79%) and 6a (86 and 75%) showed 
higher antiproliferative activity than Dox (63 and 73%) against 
HCT-116 and CCRF-CEM cells, respectively. Furthermore, 
compound 6d (86%) was more active than Dox against HCT-116 
cells and was consistently active against CCRF-CEM and MDA-
MB-468 cells. Compound 5i that showed high antiproliferative 
activity against SK-N-MC and T-47D in the previous assay was 
consistently cytotoxic against HCT-116 (71%) and CCRF-CEM 
(77%) cells. 
 
Compounds 5e, 5g, 5h, 5f, and 6g demonstrated modest 
antiproliferative activities (40-74%) against all three cell lines. 
Furthermore, nine compounds 5b, 5d, 5h, 6b, 6c, 6e, and 6f 
exhibited significantly higher antiproliferative activity against 
HCT-116 and MDA-MB-468 cell lines that CCRF-CEM cells. 
For example, 6c, 6e, and 6f inhibited HCT-116 by 68, 63, 68% 
and MDA-MB-468 cells by 66, 60, and 71%, respectively. The 
presence of either chlorine or bromine groups on both rings 
decreased the antiproliferative activity as shown in compounds 
6b-c, 6e, 6f.  
In conclusion, a series of 18 novel xanthone sulphonamide 
derivatives were synthesized and evaluated for their anticancer 
activity against a panel of cancer cell lines. Compound 5i 
containing a 4-methoxy group was more antiproliferative than 
etoposide against SK-N-MC and T-47D cells. Furthermore, the 
assay results showed that pentafluoro derivatives 5a and 6a had 
higher antiproliferative activity against HCT-116 and CCRF-
CEM cells than Dox. Structure-activity relationship studies 
provided insights for designing the next generation of xanthone 
benzenesulfonamide hybrid prototypes and development of new 
lead compounds as antiproliferative agents. 
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